Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma

Ann Hematol. 2012 Sep;91(9):1393-401. doi: 10.1007/s00277-012-1469-3. Epub 2012 Apr 29.

Abstract

In the present study, we evaluated the ophthalmologic outcomes of 24 patients who received chemotherapy and/or radiotherapy for the treatment of non-conjunctival ocular adnexal mucosa-associated lymphoid tissue-type (MALT) lymphoma. Ophthalmologic outcomes were assessed in patients who received chemotherapy and/or radiotherapy from March 2004 until May 2010. Outcomes were determined according to common symptoms following chemotherapy and/or radiotherapy, which consisted of decreased visual acuity, dry eye symptoms, retinopathy, optic neuropathy, increased intraocular pressure, and blepharitis. Nine patients received chemotherapy alone, eight patients received radiotherapy alone, and seven patients received chemotherapy with additional radiotherapy (chemoradiation therapy). Patients treated by chemotherapy alone showed better ophthalmologic outcome scores (mean score, 1.56) than those treated by radiation alone or chemoradiation therapy (mean score, 4.01). In conclusion, the treatment of ocular adnexal lymphoma including radiotherapy showed poor ophthalmologic outcomes due to radiation-induced complications. Recently, many new treatment options have emerged, such as immunotherapy or radioimmunotherapy. In the future study, to select a better treatment modality with fewer complications, well-designed prospective trials with ophthalmologic outcomes are needed.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blepharitis / chemically induced
  • Blepharitis / epidemiology
  • Blepharitis / etiology
  • Cataract / chemically induced
  • Cataract / epidemiology
  • Cataract / etiology
  • Chemoradiotherapy
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Eye Neoplasms / drug therapy
  • Eye Neoplasms / radiotherapy
  • Eye Neoplasms / therapy*
  • Female
  • Hematologic Diseases / chemically induced
  • Humans
  • Lacrimal Apparatus Diseases / drug therapy
  • Lacrimal Apparatus Diseases / radiotherapy
  • Lacrimal Apparatus Diseases / therapy
  • Lymphoma, B-Cell, Marginal Zone / drug therapy
  • Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • Lymphoma, B-Cell, Marginal Zone / therapy*
  • Male
  • Middle Aged
  • Ocular Hypertension / chemically induced
  • Ocular Hypertension / epidemiology
  • Ocular Hypertension / etiology
  • Optic Nerve Diseases / chemically induced
  • Optic Nerve Diseases / epidemiology
  • Optic Nerve Diseases / etiology
  • Orbital Neoplasms / drug therapy
  • Orbital Neoplasms / radiotherapy
  • Orbital Neoplasms / therapy*
  • Peripheral Nervous System Diseases / chemically induced
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Radiotherapy / adverse effects*
  • Radiotherapy, Adjuvant / adverse effects
  • Retinal Diseases / chemically induced
  • Retinal Diseases / epidemiology
  • Retinal Diseases / etiology
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Vincristine / therapeutic use
  • Xerophthalmia / chemically induced
  • Xerophthalmia / epidemiology
  • Xerophthalmia / etiology

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • COP protocol 2